Somewhat Favorable News Coverage Somewhat Unlikely to Impact Chemed Corp. (CHE) Stock Price
News headlines about Chemed Corp. (NYSE:CHE) have been trending somewhat positive on Thursday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Chemed Corp. earned a news impact score of 0.12 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.3609658269898 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:
- $75 Million Settlement Reached in Hospice False Claims Case (homehealthcarenews.com)
- ETFs with exposure to Chemed Corp. : November 14, 2017 (finance.yahoo.com)
- Chemed Corp. (CHE) Insider Sells $2,310,000.00 in Stock (americanbankingnews.com)
- Company settles suit over hospice patients, disputes claims (stltoday.com)
- Vitas Hospice and Chemed Corporation Settle Largest-Ever FCA Claim Against a Hospice (jdsupra.com)
Several research analysts have recently weighed in on CHE shares. KeyCorp reissued a “hold” rating on shares of Chemed Corp. in a research report on Friday, October 27th. Zacks Investment Research lowered Chemed Corp. from a “buy” rating to a “hold” rating in a research report on Tuesday, September 26th. Royal Bank Of Canada reissued a “hold” rating and issued a $209.00 price objective on shares of Chemed Corp. in a research report on Tuesday, October 3rd. BidaskClub lowered Chemed Corp. from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Finally, Oppenheimer Holdings, Inc. lifted their price objective on Chemed Corp. from $220.00 to $225.00 and gave the stock an “outperform” rating in a research report on Friday, October 27th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Chemed Corp. currently has a consensus rating of “Hold” and a consensus price target of $236.00.
Shares of Chemed Corp. (NYSE:CHE) opened at $232.42 on Thursday. The company has a debt-to-equity ratio of 0.15, a current ratio of 0.50 and a quick ratio of 0.48. The company has a market capitalization of $3,710.00, a PE ratio of 28.49, a PEG ratio of 4.89 and a beta of 1.14. Chemed Corp. has a 12 month low of $145.09 and a 12 month high of $235.96.
Chemed Corp. (NYSE:CHE) last issued its earnings results on Thursday, October 26th. The company reported $2.15 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.00 by $0.15. The company had revenue of $417.40 million during the quarter, compared to the consensus estimate of $414.34 million. Chemed Corp. had a return on equity of 27.69% and a net margin of 4.62%. The firm’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same period last year, the business posted $1.73 EPS. analysts anticipate that Chemed Corp. will post 4.73 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Monday, December 4th. Shareholders of record on Monday, November 13th will be paid a dividend of $0.28 per share. The ex-dividend date is Friday, November 10th. This represents a $1.12 dividend on an annualized basis and a yield of 0.48%. Chemed Corp.’s dividend payout ratio (DPR) is currently 24.94%.
In other Chemed Corp. news, insider Nicholas Michael Westfall sold 10,000 shares of Chemed Corp. stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $231.00, for a total transaction of $2,310,000.00. Following the completion of the transaction, the insider now owns 13,351 shares in the company, valued at approximately $3,084,081. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Naomi C. Dallob sold 1,900 shares of Chemed Corp. stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $231.00, for a total value of $438,900.00. Following the transaction, the vice president now owns 10,426 shares of the company’s stock, valued at approximately $2,408,406. The disclosure for this sale can be found here. Insiders have sold a total of 25,650 shares of company stock valued at $5,790,193 in the last quarter. Company insiders own 4.90% of the company’s stock.
About Chemed Corp.
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.